|
KMID : 0356419990170010045
|
|
Journal of Korean Andrology
1999 Volume.17 No. 1 p.45 ~ p.50
|
|
|
Long-Term Efficacy and Safety of Terazosin in the Symptomatic Treatment of Benign Prostatic Hyperplasia
|
|
Chung Byung-Ha
Chung Hyun-Jik
Hong Sung-Joon
|
|
|
Abstract
|
|
|
Purpose: To evaluate the long-term efficacy and safety of terazosin, a selective
alpha-1 blocker, in the treatment of benign prostatic hyperplasia (BPH) in Korea.
Patients and Methods: This was a 24-month, open-label, baseline-controlled study
with patients evaluated at 1- to 6-month intervals. A total of 228 male patients aged 50
years or older who had clinical evidence of BPH were enrolled. Terazosin was given
starting at 1 ㎎ per day and then maintained at a dose of 3-4 ㎎ daily. Efficacy, as
judged by the International Prostate Symptom Score (IPSS), and the blood pressure
(BP) were assessed according to the schedule.
Results: A total of 126 patients completed the study, with the most common reasons
for withdrawal being loss to follow-up or adverse events. The mean IPSS was reduced
by 35% or greater. In the hypertensive patients, the mean systolic BP was reduced by
11.9% (-18 ㎜Hg) and the mean diastolic BP by 16.8% (-17 ㎜Hg), whereas in
normotensive patients, the reductions were 4.0% (-5 ㎜Hg) and 1.2% (-1 ㎜Hg),
respectively. There were no significant differences in the IPSS improvement in these
two groups. Forty-nine adverse events were reported by 32 patients, the most common
being dizziness, postural hypotension, and headache.
Conclusion: This study suggests that terazosin is effective and well tolerated in
long-term treatment of patients with BPH.
|
|
|
KEYWORD
|
|
|
Alpha-1 antagonists, Prostatic hyperplasia, Terazosin,
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|